$9.01
Enfusion, which produces Cloud-based investment management software, wrapped its IPO, selling 15.322 million shares at $17 per share, the high end of its announced price range.
Shares of Enfusion will begin trading on the NYSE later today under the ticker symbol ENFN, but shares are available for limit orders on Robinhood and other platforms.
Our top picks for where to buy Enfusion stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Enfusion stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ENFN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Enfusion stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Enfusion stock price (NYSE: ENFN)
Use our graph to track the performance of ENFN stocks over time.Enfusion shares at a glance
Latest market close | $9.08 |
---|---|
52-week range | $7.52 - $10.45 |
50-day moving average | $8.51 |
200-day moving average | $8.87 |
Wall St. target price | $9.31 |
PE ratio | 223 |
Dividend yield | N/A |
Earnings per share (TTM) | $0.04 |
Is it a good time to buy Enfusion stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Enfusion price performance over time
Historical closes compared with the close of $8.76 from 2024-10-18
1 week (2024-10-15) | -1.79% |
---|---|
1 month (2024-09-20) | -2.45% |
3 months (2024-07-22) | -4.78% |
6 months (2024-04-22) | -5.09% |
1 year (2023-10-20) | 8.76 |
---|---|
2 years (2022-10-21) | -29.13% |
3 years (2021-10-22) | 19.92 |
5 years (2019-10-18) | N/A |
Is Enfusion stock undervalued or overvalued?
Valuing Enfusion stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enfusion's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Enfusion's P/E ratio
Enfusion's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 223x. In other words, Enfusion shares trade at around 223x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Enfusion's P/E ratio is best considered in relation to those of others within the software - application industry or those of similar companies.
- X Financial Class A (XYF.US): 1.68
- Moneygram Int (MGI.US): 32.32
- PayPal (PYPL.US): 19.65
Enfusion's EBITDA
Enfusion's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.8 million.
The EBITDA is a measure of a Enfusion's overall financial performance and is widely used to measure a its profitability.
To put Enfusion's EBITDA into context you can compare it against that of similar companies.
- X Financial Class A (XYF.US): USD$1.6 billion
- Moneygram Int (MGI.US): USD$189.6 million
- PayPal (PYPL.US): USD$5.9 billion
Enfusion financials
Revenue TTM | $188.4 million |
---|---|
Operating margin TTM | 5.47% |
Gross profit TTM | $103.2 million |
Return on assets TTM | 3.74% |
Return on equity TTM | 6.61% |
Profit margin | 1.99% |
Book value | $0.70 |
Market Capitalization | $831.4 million |
TTM: trailing 12 months
Enfusion share dividends
We're not expecting Enfusion to pay a dividend over the next 12 months.
You may also wish to consider:
- X Financial Class A (XYF.US) (5.07% forward annual dividend yield)
Enfusion share price volatility
Over the last 12 months, Enfusion's shares have ranged in value from as little as $7.52 up to $10.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enfusion's is 0.927. This would suggest that Enfusion's shares are less volatile than average (for this exchange).
To put Enfusion's beta into context you can compare it against those of similar companies.
- X Financial Class A (XYF.US): 0.293
- Moneygram Int (MGI.US): 0.9947
- PayPal (PYPL.US): 1.441
Enfusion overview
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. .
Frequently asked questions
nullWhat percentage of Enfusion is owned by insiders or institutions?
Currently 6.438% of Enfusion shares are held by insiders and 97.323% by institutions. How many people work for Enfusion?
Latest data suggests 1,102 work at Enfusion. When does the fiscal year end for Enfusion?
Enfusion's fiscal year ends in December. Where is Enfusion based?
Enfusion's address is: 125 South Clark Street, Chicago, IL, United States, 60603 What is Enfusion's ISIN number?
Enfusion's international securities identification number is: US2928121043
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question